Publications
(From a list of 114 publications)
The multifunctional dopamine D2/D3 receptors agonists with inhibitory activity against the full-length tau441 aggregation. Iva Ziu, Irving Rettig, Dan Luo, Aloke K. Dutta,Theresa M. McCormick,2and Sanela Martic-Milne. Accepted in Bioorganic Medicinal Chemistry, 2020.
Design, Synthesis and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease. Asma Elmabruk, Banibrata Das, Liping Xu,Tamara Antonio, Maarten E.A. Reith, Aloke K. Dutta. ACS Chemical Neuroscience. ACS Chem Neurosci. 2019 Jan 16;10(1):396-411.
Targeting alpha synuclein protein and amyloid beta by a multifunctional brain penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson's disease with dementia. Deepthi Yedlapudi, Liping Xu, Sokol Todi, Aloke Dutta. Scientific Reports, 2019 Dec 23;9(1):19648.
D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats. Aloke K. Dutta, Soumava Santra, Arman Harutyunyan, Banibrata Das, Michael Lisieski, Liping Xu, Tamara Antonio, Maarten E.A. Reith, Shane A. Perrine. European Journal of Pharmacology. 2019 Nov 5; 862: 172632.
A Novel Orally Active Triple Reuptake Inhibitor for the Treatment of Post-Traumatic Stress Disorder (PTSD): D-578 Attenuates Abnormal Fear Behavior in a Rodent Model of Traumatic Stress. Michael Lisieski, Arman Harutyunyan, Banibrata Das, Israel Liberzon, Frank P. Bymaster, Timothy Hsu, Maarten Reith, Shane A. Perrine, Aloke K. Dutta. Biological Psychiatry, 85(10):S216 · May 2019.
Alpha-synuclein aggregation modulation: An emerging approach for the treatment of Parkinson's disease. Sushil K. Singh, Aloke Dutta, and Gyan Modi. Invited Review, Future Medicinal Chemistry, 9(10):1039-1053, 2017.
D-512, a novel dopamine D2 / D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in parkinsonian rats. David Lindenbach, Banibrata Das, Melissa M. Conti, Samantha Meadows, Aloke K. Dutta, Christopher Bishop. British Journal of Pharmacology, 174(18):3058-3071, 2017.
Banibrata Das, Ashoka Kandegedara, Liping Xu, Tamara Antonio, Timothy Stemmler, Maarten Reith, Aloke Dutta. A novel iron(II) preferring dopamine agonist chelator as potential symptomatic and neuroprotective therapeutic agent for Parkinson's disease. ACS Chem. Neurosci. 2017, 8, 723-730.
Banibrata Das, Subramanian Rajagopalan, Gnanada S. Joshi, Liping Xu, Dan Luo, Julie K. Andersen, Sokol V. Todi, Aloke K. Dutta. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo. Neuropharmacology. 2017, 123, 88-99.
Juan Zhen, Tamara Antonio, Aloke K. Dutta, Dana Salley, Maarten E.A. Reith. Efficacy of hybrid tetrahydrobenzo[d]thiazole based aryl piperazines D-264 and D-301 at D2 and D3 receptors. Neurochemical Research, 2016, 41(1-2), 328-39.
Fahd Dholkawala, Chandrashekhar Voshavar, Aloke K. Dutta. Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson's disease. J. Pharmaceutics and Biopharmaceutics, 2016, 103, 62–70.
Deepthi Yedlapudi, Gnanada Joshi, Dan Luo, Sokol Todi, Aloke K. Dutta. Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Scientific Reports 6, Article number: 38510 (2016). doi:10.1038/srep38510.
Dan Luo, Horrick Sharma, Deepthi Yedlapudi, Tamara Antonio, Maarten E.A. Reith, Aloke K. Dutta. Novel multifunctional dopamine D2/D3 receptors agonists as modulator of aggregation of alpha synuclein protein with potential neuroprotective property. Bioorganic & Medicinal Chemistry, 2016, 24, 5088–5102.
Soumava Santra, Horrick Sharma, Seenuvasan Vedachalam, Tamara Antonio, Maarten Reith, Aloke Dutta. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl) amino)tetrahydro-2H-pyran-4-ol molecular template. Bioorg. Med. Chem. 2015, 23, 821-828.
Banibrata Das, Gyan P. Modi, Aloke K. Dutta. Dopamine D3 agonists in the Treatment of Parkinson's Disease. Curr. Top. Med. Chem., 2015, 15(10), 908-926.
Juan Zhen, Tamara Antonio, Solav Ali, Kim A. Neve, Aloke K. Dutta, Maarten E.A. Reith. Use of radiolabeled antagonist assays for assessing agonism at D2 and D3 dopamine receptors: Comparison with functional GTPγs assays. J. Neurosci. Methods. 2015, 248, 7-15.
Chandrasekhar Voshavar, Mrudang Shah, Liping Xu, Aloke Dutta. Assessment of protective role of multifunctional dopamine agonist D-512 against Oxidative stress produced by depletion of Glutathione in PC12 cells: Implication in neuroprotective therapy for Parkinson's disease. Neurotoxicity Research, 2015, 1-17.
Soumava Santra, Horrick Sharma, Aloke Dutta. Triple Uptake Inhibitor as a potential new generation antidepressant agents. Future Med. Chem. 2015, 7(17), 2385-2406.
Banibrata Das, Seenuvasan Vedachalam, Dan Luo, Tamara Antonio, Maarten Reith, Aloke Dutta. Development of a highly potent D2/D3 agonist and a partial agonist from structure-activity relationship study of N(6)-(2-4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: Implication in the treatment of Parkinson's disease. J. Med. Chem. 2015, 58(23), 9179-9195.
Gyan Modi, Tamara Antonio, Maarten Reith, Aloke Dutta. Structural Modifications of Neuroprotective Anti-Parkinsonian (−)‑N6‑(2-(4-(Biphenyl-4-yl)piperazin-1-yl)-ethyl)‑N6‑propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): An Effort toward the Improvement of in Vivo Efficacy of the Parent Molecule. J. Med. Chem. 2014, 57, 1557−1572.
Mrudang Shah, Chandrasekhar Voshavar, Liping Xu, Subramanian Rajagopalan, Julie Andersen, Aloke Dutta. High affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA induced apoptotic cell death and rescued dopaminergic neurons in the MPTP mouse model of Parkinson's disease. J. Neurochem. 2014, 131, 74–85.
Horrick Sharma, Soumava Santra, Joy Debnath, Bhaskar Gopishetty, Tamara Antonio, Maarten Reith, Aloke Dutta. Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol : Synthesis, biological characterization, and development of a pharmacophore model. Bioorg. Med. Chem. 2014, 22, 311–324.
Gyan Modi, Chandrashekhar Voshavar, Mrudang Shah, Tamara Antonio, Maarten Reith, Aloke Dutta. Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: Modulator of toxicity of Alpha synuclein aggregates. ACS Chem. Neurosci. 2014, 5, 700–717.
Gyan Modi, Horrick Sharma, Prashant S. Kharkar, Aloke Dutta. Understanding the structural requirements of hybrid (S)-6-((2-(4-phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol and its analogs as D2/D3 receptor ligands. A three-dimensional quantitative structure-activity relationship (3D QSAR) investigation. Medchemcomm. 2014, 5(9), 1384-1399.
Aloke Dutta, Soumava Santra, Horrick Sharma, Chandrasekhar Voshavar, Liping Xu, Omar Mabrouk, Tamara Antonio, Maarten Reith. Pharmacological and behavioral characterization of an orally active triple reuptake inhibitor D-473: Effects of drug on extracellular levels of dopamine, serotonin and norepinephrine. PLoS One, 2014, 9, e113420.
Eldo Kuzhikandathil, Samantha Cote, Soumava Santra, Aloke K. Dutta. Interaction of D3 preferring agonist (─)-N6-(2-(4-(Biphenyl-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D2L, D2S and D3 receptors: Potent stimulation of mitogen-activated protein kinases and G-protein coupled inward rectifier potassium channels. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386(2), 97-105.
Soumava Santra, Liping Xu, Mrudang Shah, Mark Johnson, Aloke Dutta. D-512 and D-440 as novel multifunctional dopamine agonists: Characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model. ACS Chem. Neurosci. 2013, 4(10), 1382–1392.
Soumava Santra, Liping Xu, Mark Johnson, Sanjib Gogoi, Tamara Antonio, Maarten E. A. Reith, Aloke K. Dutta. (2013) Approach towards development of multifunctional drugs as an effective strategy for treatment of Parkinson's disease. In L. Eiden (Ed.), Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium 2012, 148-149, Oxford, UK: Elsevier.
Bhaskar Gopishetty, Suhong Zhang, Prashant S. Kharkar, Tamara Antonio, Maarten Reith, Aloke K. Dutta. Modification of agonist binding moiety in hybrid derivative 5/ 7-{[2-(4-Aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/ -2-amino versions: Impact on functional activity and selectivity for dopamine D2/D3 receptors. Bioorg. Med. Chem. 2013, 21, 3164–3174.
Patents
1. Dutta, A. K. NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES, U.S. Patent No. 10,125,127, November 13, 2018.
2. Dutta, A. K. TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OLANALOGUES, AND NOVEL 3,6 DISUBSTITUTED PYRAN DERIVATIVES. Canadian Pat No, 2563161, January 24, 2017.
3. Dutta, A. K. Substituted pyran derivatives, US 9458124 B2, approved on Oct 4, 2016.
4. Dutta, A. K. Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives. U.S. Pat. No. US 8,937,189, January 20, 2015.
5. Dutta, A. K. Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases, U.S. Pat. No. US 9,034,877, May 19, 2015.
6. Dutta, A. K. "TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES". European Pat. No. EP 1 734948 B1, June 11, 2014.
7. Dutta, A. K. Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives. U.S. Pat. No. US 8,841,464, September 23, 2014.
8. Dutta, A. K. "Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives.", WSU 0203PUSA, U.S. Pat. No. US8,519,159 B2, August 27, 2013.
9. Dutta, A. K. "TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES". European Pat. No. EP 1 976 381 B1, July 24, 2013.
10. HYBRID 2-AMINOTETRALIN AND ARYL-SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE IN ALTERING CNS ACTIVITY. PATENT NO: US 8,227,604 B2, July 24, 2012.
11. Dutta, A. K. N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith, U.S. Pat. No. US 8,211,916, July 3, 2012.
12. Dutta, A. K. "Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives.", WSU 0203PUSA, U.S. Pat. No. US8,017,791, September 13, 2011.
13. Dutta, A. K . TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OLANALOGUES, AND NOVEL 3,6 DISUBSTITUTED PYRAN DERIVATIVES. U.S. Pat. No. US 7915433, April 4, 2011.
14. Dutta, A. K. "Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives.", WSU 0203PUSA, U.S. Pat. No. US7,915,433 B2, March 29, 2011.
15. HYBRID 2-AMINOTETRALIN AND ARYL-SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE IN ALTERING CNS ACTIVITY. U.S. Patent Appn. No. 11/235612 (WSU 0197 PUSA1). Status: Patented as U.S. Pat. No. 7,723,519. Issue Date: May 25, 2010.
16. N-AND O-SUBSTITUTED 4-[2-( DIPHENYLMETHOXY) -ETHYL]-1- (PHENYL) METHYL) PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH. U.S. Pat. No. 7,595,331, September 29, 2009.
17. N- AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-(PHENYL) METHYL) PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH. PATENT NO: US 6,995,268 B2; FEBRUARY 7 2006.
18. HYBRID 2-AMINOTETRALIN AND ARYL-SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE IN ALTERING CNS ACTIVITY. PATENT NO: US 6,982,332, JANUARY 3, 2006.
19. Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differentail cns receptor activity and behavior. Patent NO: US 7049337 B2; May 23, 2006.
